Research Charges Sample Clauses

Research Charges. If you apply to receive Research (using the Research Application Form) you will, unless agreed otherwise in any Research Application Form, be charged for such Research on an annual basis in advance. The amount of such charges will depend on the level of Research you have applied for (as indicated on your Research Application Form), subject to such charges as may be notified to you by N+1 Singer from time to time. Any increase in N+1 Singers charges for Research shall not take effect until the following annual payment and shall be notified to you not less than 10 Business Days before such annual payment is due.
Sample 1Sample 2Sample 3
AutoNDA by SimpleDocs
Research Charges a) This Research Charge and brokerage commission will be collected from the Client on the contrac tual settlement date for such Transactions (the “Collection Date”).
Sample 1
Research Charges a) Instinet will collect from the Client a Research Charge when executing Research Charge Orders.
Sample 1
Research Charges. Work performed on the Project by [*] (i) for the execution of work under this Contract and (ii) for any work requested by the FDA or other governmental authority or investigator on its behalf pertaining to a Project shall be charged at the rate specified in the Project Description.
Sample 1
Research Charges. Charges for services performed shall be charged at the rate specified in the applicable Project Summary. 4.3.3
Sample 1
Research Charges. Charges for Services performed under this Agreement by Xxxxxxx Xxxxxxx Pharma Services (i) for the execution of work on each Project and (ii) for any work requested by the FDA or other governmental authority or investigator on its behalf pertaining to a Project shall be charged at the rate specified in the applicable Project Description.
Sample 1
Research Charges. The Counterparty will collect from the underlying client a Research Charge when executing Research Charge Orders. The Client requests the Counterparty and the Counterparty agrees (for itself [and each Affiliate]) to pay such Research Charge into the RPA in accordance with the instructions and account details provided by the Client to the Counterparty from time to time. The Parties acknowledge that, for the period between collecting Research Charges relating to Research Charge Orders and the payment of such Research Charges into the RPA, and unless otherwise agreed between the Parties the Research Charges shall [not be held on trust by the Counterparty]/[shall be held in a segregated account as agreed by the parties]1. Any payments by the Counterparty to the RPA shall be without interest. The Counterparty will not have any right of set-off over Research Charges in relation to any services that the Counterparty may provide to the Client. Each reconciliation process shall cover a period of [insert number of] days and each party shall provide the other with its initial reconciliation calculations, including a list of transactions undertaken and Research Charges due, within a further [insert number of] days. The parties shall co-operate with each other, on a bona fide basis, to achieve a reconciliation of the amounts due to be paid, or paid, by the Counterparty into the RPA, and the amount that the Client expects to be paid into the RPA, prior to one day before the expiry of the [30 day]2 period permitted under FCA COBS 2.3B.19G(1)(a), and in any event without undue delay. The Parties may agree to provide and receive periodic updates on the sums due to be paid as Research Charges. The periods in this clause 2.4 may be varied with the agreement of each party. Use of an RPA Administrator or Other Third Party Where the Client has appointed an RPA Administrator, it shall notify the Counterparty of the identity of such RPA Administrator or any change of RPA Administrator in writing in a reasonably prompt manner (which may be by email). In such instances, the Client agrees that the Counterparty may share the Client’s and the Counterparty’s trade data where necessary with third parties such as the RPA Administrator, and the Client shall use reasonable efforts to ensure that any data shared with such an RPA Administrator in such an arrangement is used by the RPA Administrator only in connection with the provision of RPA administration services. For the avoidance of dou...
Sample 1
AutoNDA by SimpleDocs

Related to Research Charges

  • License Fees If so provided in the Prospectus, the Depositor may enter into a Licensing Agreement (the "Agreement") with a licensor (the "Licensor") described in the Prospectus in which the Trust(s), as consideration for the licenses granted by the Licensor for the right to use its trademarks and trade names, intellectual property rights or for the use of databases and research owned by the Licensor, will pay a fee set forth in the Agreement to the applicable Licensor or the Depositor to reimburse the Depositor for payment of the expenses. If the Agreement provides for an annual license fee computed in whole or part by reference to the average daily net asset value of the Trust assets, for purpose of calculating the accrual of estimated expenses such annual fee shall accrue at a daily rate and the Trustee is authorized to compute an estimated license fee payment (i) until the Depositor has informed the Trustee that there will be no further deposits of additional Securities, by reference to an estimate of the average daily net asset value of the Trust assets which the Depositor shall provide the Trustee, (ii) thereafter and during the calendar quarter in which the last business day of the period described in clause (i) occurs, by reference to the net asset value of the Trust assets as of such last business day, and (iii) during each subsequent calendar quarter, by reference to the net asset value of the Trust assets as of the last business day of the preceding calendar quarter. The Trustee shall adjust the net asset value (Trust Fund Evaluation) as of the dates specified in the preceding sentence to account for any variation between accrual of estimated license fee and the license fee payable pursuant to the Agreement, but such adjustment shall not affect calculations made prior thereto and no adjustment shall be made in respect thereof.

  • License Maintenance Fees COMPANY shall pay to M.I.T. the following license maintenance fees on the dates set forth below: [January 1, year] [dollar amount] [January 1, year] [dollar amount] [and each January 1 of every year thereafter] [dollar amount] This annual license maintenance fee is nonrefundable; however, the license maintenance fee may be credited to running royalties subsequently due on NET SALES earned during the same calendar year, if any. License maintenance fees paid in excess of running royalties due in such calendar year shall not be creditable to amounts due for future years.

  • Development Expenses Novartis shall be solely responsible for the costs and expenses of Developing and commercializing Licensed Products pursuant to the terms of this Agreement, except with respect to Infinity’s research, development and commercialization activities with respect to an Abandoned Profile pursuant to Section 3.3.1 (subject to Section 2.3).

  • Sublicense Fees Licensee will pay Sublicense Fees indicated in Section 3.1(e) of the Patent & Technology License Agreement on or before the Quarterly Payment Deadline for the Contract Quarter.

  • License Fee The Licensee to shall make payment of the License Fee to Licensor on the date of this Agreement. All rights granted to Licensee by Producer in the Beat are conditional upon Licensee’s timely payment of the License Fee. The License Fee is a one-time payment for the rights granted to Licensee and this Agreement is not valid until the License Fee has been paid.

  • License Maintenance Fee Beginning and each thereafter, ***** will pay Stanford a yearly license maintenance fee of $ . Yearly maintenance payments are nonrefundable.

  • Maintenance Fees All maintenance and similar fees in respect of any Purchased Assets that are due and payable prior to the Closing have been paid in full.

  • Manufacturing Costs Patheon shall be allowed to adjust the Fees: (i) for costs associated with the conversion of Granulations and Components into Drug Product (the “Conversion Costs”) in respect of the Drug Product based on the most recently available final Producers’ Price Index for Pharmaceutical Product as published by the U.S. Bureau of Labor Statistics or any governmental successor thereto (“PPI”) using the procedure set forth in Section 4.3 and (ii) for Component Costs to pass on the actual amount of any increase or decrease in such costs without xxxx-up. For each Contract Year in which Patheon is entitled to adjust the Fees Patheon shall provide Client with written notice of any change in the Fees within 30 days of receipt by Patheon of the Annual Forecast. The Parties agree that the Fees shall not be adjusted more than once per Contract Year, however this limitation shall not include price adjustments under section 4.3 or 4.4. In addition, notwithstanding anything herein to the contrary, Manufacturing Fees associated with Conversion Costs shall not be increased by greater than [***]% per annum in any Contract Year during the Term. There shall be no similar limitation in terms of increases in Component Costs which shall be passed on to Client in an amount equal to the actual increase paid by Patheon without markup.

  • Know-How Royalty Notwithstanding the provisions of Section 5.4.1(a), in countries where the sale of Product by Merck or its Related Parties would not infringe a Valid Patent Claim, Merck shall pay royalty rates that shall be set at [***] of the applicable royalty rate determined according to Section 5.4.1(a). Such royalties shall be calculated after first calculating royalties under Section 5.4.1(a).

  • Development Costs With respect to activities prior to the Amendment Effective Date, each Party was to pay [*] of the total Direct Development Costs of a Product incurred in accordance with the Development Budget (as defined in the Original Agreement). Notwithstanding anything in this Article 6 of this Agreement or in any other provision of this Agreement to the contrary, with respect to activities on and after the Amendment Effective Date, subject to Sections 3.1.2, Alimera will be solely responsible for, and shall pay one hundred percent (100%) of, all development costs of a Product, including Direct Development Costs. Notwithstanding anything in this Article 6 of this Agreement or in any other provision of this Agreement to the contrary, (i) all payments owing by CDS hereunder with respect to development activities prior to the Amendment Effective Date are hereby deemed fully paid by CDS (or waived, to the extent such waiver may be required), including any Development Payments, Compounded Development Payments, Determined Disputed Costs and Compounded Disputed Costs (as all defined in the Original Agreement), further including any penalties and interest which might have accrued with respect thereto, and further including all CDS payments deferred pursuant to that February 11, 2008 letter agreement sent by CDS and executed by CDS and Alimera regarding deferral of payments under the Original Agreement as of such date; (ii) all payments owing by Alimera hereunder with respect to development activities prior to the Amendment Effective Date are hereby deemed fully paid by Alimera (or waived, to the extent such waiver may be required), including any Development Payments, Compounded Development Payments, Determined Disputed Costs and Compounded Disputed Costs (as all defined in the Original Agreement), and further including any penalties and interest which might have accrued with respect thereto; and (iii) subject to Sections 3.1.1 and 3.1.2, from and after the Amendment Effective Date, CDS will have no liability whatsoever hereunder for any past, present or future development costs, including Direct Development Costs (which includes those incurred before, on and after the Amendment Effective Date), and instead Alimera shall have sole liability therefor.

Time is Money Join Law Insider Premium to draft better contracts faster.